Bisoprolol fumarate
Concor Cor 5 and Emconcor Cor are different trade names for the same drug.
The active substance of Concor Cor 5 is bisoprolol fumarate. Bisoprolol belongs to a group of medicines called beta-blockers. These medicines affect the body's response to certain nerve impulses, especially in the heart. As a result, bisoprolol slows down the heart rate and thus increases the efficiency of the heart in pumping blood throughout the body. Bisoprolol at a dose of 5 mg lowers high blood pressure.
Heart failure occurs when the heart muscle is weak and cannot pump enough blood to meet the body's needs.
Concor Cor 5 is used to treat stable, chronic heart failure.
Concor Cor 5 is used to treat high blood pressure or angina pectoris (chest pain caused by insufficient blood supply to the heart) .
Concor Cor 5 should not be taken in the following cases:
If any of the following conditions occur, the patient should talk to their doctor before starting Concor Cor 5; the doctor may decide that special caution is necessary (e.g., additional medication or more frequent medical check-ups):
In addition, the patient should tell their doctor if they plan to:
Concor Cor 5 is not recommended for use in children and adolescents.
The patient should tell their doctor about all medicines they are currently taking or have recently taken, as well as any medicines they plan to take.
Concor Cor 5 should not be taken with the following medicines without special recommendation by the doctor:
Before taking the following medicines with Concor Cor 5, the patient should talk to their doctor, as the doctor may recommend more frequent medical check-ups:
There is a risk that taking Concor Cor 5 during pregnancy may harm the baby.
If the patient is pregnant or breastfeeding, thinks they may be pregnant, or plans to have a baby, they should consult their doctor or pharmacist before taking this medicine. The doctor will decide whether Concor Cor 5 can be taken during pregnancy.
It is not known whether bisoprolol passes into breast milk, so breastfeeding is not recommended during treatment with Concor Cor 5.
The medicine, depending on how it is tolerated, may impair the ability to drive or operate machinery. The patient should be particularly careful at the beginning of treatment, after increasing the dose, or when changing medicines, as well as when combining the medicine with alcohol.
This medicine should always be taken according to the doctor's recommendations. In case of doubts, the patient should consult their doctor or pharmacist.
During treatment with Concor Cor 5, regular medical check-ups are necessary. This is especially important at the beginning of treatment, during dose increases, and when stopping treatment.
The tablet should be taken in the morning with food or independently of food, washed down with water. The tablets should not be chewed. Scored tablets can be divided into two equal doses.
The medicine is available in the following doses: 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, 10 mg.
Treatment of stable, chronic heart failure
The doctor will start treatment with bisoprolol at a low dose, which will be gradually increased - the doctor will decide how to increase the dose. The recommended initial dose is 1.25 mg once a day.
The dose is increased at intervals of two weeks or more to a dose of 2.5 mg, 3.75 mg, 5 mg, 7.5 mg, and 10 mg once a day. This is usually done as follows:
The maximum recommended daily dose is 10 mg of bisoprolol.
Depending on how the medicine is tolerated, the doctor may recommend extending the time between dose increases. If the disease worsens or the medicine is not tolerated, it may be necessary to reduce the dose again or stop treatment. In some patients, a maintenance dose lower than 10 mg of bisoprolol may be sufficient.
The doctor will determine the appropriate course of action.
Treatment of high blood pressure and angina pectoris
In both indications, the usual dose is one Concor Cor 5 tablet (equivalent to 5 mg of bisoprolol fumarate) once a day.
If necessary, the doctor may increase the dose to two Concor Cor 5 tablets (equivalent to 10 mg of bisoprolol fumarate) once a day.
The maximum recommended dose is 20 mg once a day.
Treatment of high blood pressure and angina pectoris
In patients with mild to moderate liver or kidney impairment, there is usually no need to modify the dosage. In patients with severe kidney failure and in patients with severe liver failure, a dose higher than 10 mg of bisoprolol should not be used.
Experience with bisoprolol in patients undergoing dialysis is limited; however, there is no evidence that the dosage needs to be modified.
Treatment of stable, chronic heart failure
Special caution should be exercised when increasing the dose of the medicine.
Dose adjustment is not necessary.
Concor Cor 5 is not recommended for use in children and adolescents.
Treatment with Concor Cor 5 is usually long-term.
If treatment needs to be stopped, the doctor will usually recommend gradual reduction of the dose, otherwise, the disease may worsen.
In case of taking a higher dose of Concor Cor 5 than recommended, the patient should immediately inform their doctor. The doctor will decide what actions to take.
Symptoms of overdose include: slow heart rate, breathing difficulties, significant drop in blood pressure, dizziness, or seizures (caused by decreased blood sugar levels).
The patient should not take a double dose to make up for a missed dose. The next day, they should take the recommended dose.
The patient should never stop taking Concor Cor 5 unless their doctor recommends it. Otherwise, the disease may worsen.
In case of any further doubts about taking this medicine, the patient should consult their doctor or pharmacist.
Like all medicines, Concor Cor 5 can cause side effects, although not everybody gets them.
Very common(occurring in at least 1 in 10 patients):
Common(occurring less frequently than 1 in 10 patients):
Only for patients with high blood pressure or angina pectoris:
* these symptoms occur mainly at the beginning of treatment. They are usually mild and disappear within 1-2 weeks.
Uncommon(occurring less frequently than 1 in 100 patients):
Rare(occurring less frequently than 1 in 1000 patients):
Very rare(occurring less frequently than 1 in 10,000 patients):
Reporting side effects
If side effects occur, including any side effects not listed in the leaflet, the patient should tell their doctor or pharmacist. Side effects can be reported directly to the Department of Monitoring of Adverse Reactions to Medicinal Products of the Office for Registration of Medicinal Products, Medical Devices, and Biocidal Products:
Jerozolimskie Avenue 181C, 02-222 Warsaw
phone: +48 22 49 21 301
fax: +48 22 49 21 309
website: https://smz.ezdrowie.gov.pl
By reporting side effects, more information can be collected on the safety of the medicine.
The medicine should be stored out of sight and reach of children.
Do not use this medicine after the expiry date stated on the packaging.
The expiry date refers to the last day of the month.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. The patient should ask their pharmacist how to dispose of medicines that are no longer needed. This will help protect the environment.
Concor Cor 5 is a yellowish-white, heart-shaped, film-coated tablet with a score line on both sides of the tablet.
Each pack contains 28 or 56 film-coated tablets.
For more detailed information, the patient should contact the marketing authorization holder or the parallel importer.
Merck, S.L., María de Molina 40, 28006 Madrid, Spain
Merck Healthcare KGaA, Frankfurter Strasse 250, D-64293 Darmstadt, Germany
Merck, S.L., Polígono Merck, 08100 Mollet del Vallés (Barcelona), Spain
PharmaVitae Sp. z o.o. sp. k., ul. E. Orzeszkowej 3/35, 59-820 Leśna
Pharma Innovations Sp. z o.o., ul. Jagiellońska 76, 03-301 Warsaw
LABOR Pharmaceutical-Chemical Enterprise Sp. z o.o., ul. Długosza 49, 51-162 Wrocław
Medezin Sp. z o.o., ul. Zbąszyńska 3, 91-342 Łódź
CANPOLAND Joint-Stock Company, ul. Beskidzka 190, 91-610 Łódź
SHIRAZ PRODUCTIONS Sp. z o.o., ul. Tymiankowa 24/28, 95-054 Ksawerów
Spanish marketing authorization number:869750.2
Parallel import authorization number:352/17
Date of leaflet approval: 20.10.2022
[Information about the trademark]
Need help understanding this medicine or your symptoms? Online doctors can answer your questions and offer guidance.